BBNX
Beta Bionics, Inc.
NASDAQ · Healthcare · Medical - Equipment & Services · US
$19.58
−1.71%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.9x
Market Cap
$880.90M
MomentumView details →
1D Return
−1.71%
YTD Return
−35.64%
RSI (14)
60.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.9x
Market Cap
$880.90M
RSI (14)
60.0
MomentumView details →
1D Return
−1.71%
YTD Return
−35.64%
SummaryUpdated Jun 1, 2026
Beta Bionics, Inc. (NASDAQ:BBNX) is a commercial-stage medical device company founded in 2015 and based in Irvine, California. The company specializes in developing automated insulin delivery systems for people with diabetes, with its flagship product being the <b>iLet Bionic Pancreas</b>. Beta Bionics went public on January 30, 2025, representing a significant milestone for the company as it transitions from development to commercial expansion in the diabetes management market.
Similar companies
Latest newsMore news →